Univariate and multivariate analysis of OS in patients with HL-SCLC.

Univariate and multivariate analysis of OS in patients with HL-SCLC.</p

Causes of deaths.

(a) Causes of deaths among HL-NSCLC; (b) Causes of deaths among HL-SCLC; (c) Causes of deaths among NSCLC-1; (d) Causes of deaths among SCLC-1.</p

Patient characteristics at the time of SCLC diagnosis.

Patient characteristics at the time of SCLC diagnosis.</p

Univariate and multivariate analysis of OS in patients with HL-NSCLC.

Univariate and multivariate analysis of OS in patients with HL-NSCLC.</p

Patient selection flow.

ObjectiveThe study aimed to compare the characteristics and prognosis between patients with second primary lung cancer following Hodgkin’s lymphoma and those with primary lung cancer.Materials and methodsUsing the SEER 18 database, the characteristics and prognosis were compared between the second primary non-small cell lung cancer following Hodgkin’s lymphoma (HL-NSCLC) (n = 466) and the first primary non-small cell lung cancer (n = 469,851)(NSCLC-1), as well as between the second primary small cell lung cancer following Hodgkin’s lymphoma (n = 93) (HL-SCLC) and the first primary small cell lung cancer (n = 94,168) (SCLC-1). Comparisons of categorical variables were performed using Chi-square or Fisher’s test. Continuous variables were compared using the Mann-Whitney U test. Overall survival (OS) was estimated using the Kaplan-Meier method, and the difference between groups was analyzed by log-rank test.ResultsHL-NSCLC group had more males than NSCLC-1 group, and the median age of HL-NSCLC group was younger than that of NSCLC-1 group. Patients with HL-NSCLC showed inferior OS than those with NSCLC-1 (median: 10 months vs. 11 months, P = 0.006). Both HL-SCLC and SCLC-1 groups had poor prognosis, with median OS of 7 months (P = 0.4). The 3-year cumulative risks of death from any cause for patients with the latencies from HL to NSCLC of 0 to 5 years, >5 to 10 years, >10 to 15 years, >15 to 20 years, and>20 years were 71.8%, 82.6%, 86.8%, 85.7% and 78.5%, respectively(P = 0.020).ConclusionHL-NSCLC patients had worse prognosis than NSCLC-1 patients, while HL-SCLC patients shared similar characteristics and survival with SCLC-1 patients.</div

Patient characteristics at the time of HL diagnosis among HL-NSCLC and HL-SCLC.

Patient characteristics at the time of HL diagnosis among HL-NSCLC and HL-SCLC.</p

Comparison of overall survival between HL-LC and LC-1.

Comparison of overall survival between HL-LC and LC-1.</p

Patient characteristics at the time of NSCLC diagnosis.

Patient characteristics at the time of NSCLC diagnosis.</p

The cumulative risk of death based on the latency between diagnoses of HL and LC.

(a) The cumulative risk of death from any cause based on the latency between diagnoses of HL and NSCLC; (b) The cumulative risk of death from NSCLC based on the latency between diagnoses of HL and NSCLC; (c) The cumulative risk of death from any cause based on the latency between diagnoses of HL and SCLC; (d) The cumulative risk of death from SCLC based on the latency between diagnoses of HL and SCLC.</p

Kaplan-Meier estimates of OS.

(a) Comparison of OS between HL-NSCLC and NSCLC-1; (b) Comparison of OS between HL-NSCLC and NSCLC-1 according to lung cancer stage; (c) Comparison of OS between HL-SCLC and SCLC-1; (d) Comparison of OS between HL-SCLC and SCLC-1 according to lung cancer stage.</p